1. Aidoo A, Lyn-Cook LE, Morris SM, Kodell RL, Casciano DA (1991) Comparative study of intracellular glutathione content in rat lymphocyte cultures treated with 2-mercaptoethanol and interleukin-2. Cell Biol Toxicol 7:215
2. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM (2003) A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma [E3695]: an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 22:708
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105
4. Barberá-Guillem E, Sampsel JW (2003) Immune-promoted tumor cell invasion and metastasis. In: Llombart-Bosch A, Felipo V (eds) New trends in cancer for the 21st century. Kluwer Academic, New York
5. Bendetto JP, Ortone JP, Voulot C, Khatchadourian C, Prota, Thivolet J (1981) Role of thiol compounds in mammalian melanin pigmentation: Part I. Reduced and oxidized glutathione. J Invest Dermatol 77:402